President, Chief Executive Officer and Director
Dr. Carlson has substantial leadership experience from startup to full P&L line management, sales and marketing, business and new product development, distribution management, and international operations. Prior to joining WaferGen in May 2015 as Chief Executive Officer Dr. Carlson served as President & CEO of Asuragen, Inc., a privately-held molecular diagnostics company. While at Asuragen, Inc., Dr. Carlson was a co-founder of Mirna Therapeutics, a spin-out of Asuragen, which has developed novel miRNA-based therapeutics currently in Phase I clinical trials for liver and other cancers. Prior to this, he served in increasingly senior positions at Abbott Laboratories over a 20-year period. Dr. Carlson's various roles at Abbott included Global General Manager and Vice President Molecular Diagnostics of Vysis, a wholly-owned subsidiary of Abbott Laboratories. Dr. Carlson also established strategic alliances with Genentech, Roche and Novartis. His last position at Abbott was Vice President, Business Development & Licensing, Global Medical Products, where he was responsible for M&A, licensing and divestiture of pharmaceutical products linked to medical device technologies. Dr. Carlson received his Ph.D. in Botany from Southern Illinois University at Carbondale.
Michael P. Henighan
Chief Financial Officer
Michael P. Henighan joined WaferGen in August 2014 as Chief Financial Officer. Prior to joining Wafergen, Michael was a founder and Chief Financial Officer of Aplegen, Inc. from February 2011 through August 2015. Prior to joining Aplegen Michael was the Alpha Innotech, Inc., a publicly traded life science imaging trading company, Chief Financial Officer from August 2008 to October 2009 and Corporate Controller from May of 2008 to August 2008, Michael was Vice President and Corporate Controller at HemoSense, Inc., a publicly traded medical device company, from May 2005 to May 2008 and Corporate Controller at Cholestech Corp., a publicly traded medical device company, from July 1997 to May 2005. Prior to 1997, he also held senior management positions with Solectron, Applied Biosystems, and Motorola. Michael earned his BS in Accounting from California State University, Los Angeles.
Maithreyan Srinivasan, Ph.D.
Chief Technology Officer
Maithreyan Srinivasan (Srini) joined WaferGen in January 2014 as a technology consultant and was promoted to Chief Technology Officer in May 2014. Earlier in his career, Srini worked for CuraGen and Roche 454 in a series of R&D roles of increasing responsibility to help launch three generations of 454 sequencers. He also co-led the first whole human genome sequencing effort on a 2nd generation DNA sequencer. Prior to joining WaferGen, Srini held the position of Senior Director of Genomics R&D at Agilent Technologies, where he lead global R&D efforts in Oligo Library Synthesis, Microarray applications and technologies, Targeted sequencing using SureSelect/Haloplex, Bioreagents associated with cloning, mutagenesis, PCR, qPCR and associated application software (SureDesign, Cytogenomics and SureCall). Srini holds a Ph.D in Biochemistry from Colorado State University and BSc and MSc degrees from University of Madras and University of Poona (India), respectively.
Senior Vice President, Engineering
Syed joined WaferGen in October 2009 with more than 20 years of experience in leading engineering teams and developing successful products and product lines in the life sciences and semiconductor industries. As vice president of engineering he is responsible for the engineering and development of the SmartChip System, and for overseeing the transfer of manufacturing of the instrument and chip products.
Prior to joining WaferGen, Syed was vice president of engineering at Microfluidic System Inc. where he was responsible for the development and manufacturing of instruments for the Biowatch program for homeland security. Previously, he was at Caliper Life sciences for eight years, where he successfully led the development of the Caliper 250 HTS system that integrated microfluidics chip, optical detection and robotics; the LC 3000; and Lab Chip GX, Desk Top Profiler - products that are recognized as leading microfluidics systems for life science research. He also has experience developing single wafer products, which he achieved while at Alcatel Comptech. His engineering and development experience spans from micro fluidics instrumentation, PCR, sample preparation, chip and chip products.
Syed is a co-inventor/inventor on 9 U.S. patents, and has a BS in Chemical engineering from Texas A&M University, Texas.
Jude Dunne, Ph.D.
Vice President, Product Development
Jude Dunne, Ph.D., joined WaferGen in July 2010 and has over 16 years of experience in product development spanning multiple roles and industries. In his role as Vice President, Jude has expanded responsibility in overseeing the integration of new assays and applications on the WaferGen Platform as well as continuing to oversee process development and consumables manufacturing operations.
Prior to joining WaferGen, Jude has held positions with Microfluidic Systems and Caliper Life Sciences with responsibility in product development, project management, system integration, validation and product support as well as transfer to production of assays and products into next generation life sciences devices.
Jude holds a Ph.D. in Chemical Engineering from the University of Pennsylvania and is named on several US patents.
Vice President, Sales
Andy Moye joined WaferGen in May 2015 and has 18 years of sales, operations, and business development experience. Prior to joining WaferGen, Andy was the Vice-President of Sales, Business Development, and Strategy at CombiMatrix, a leading national reproductive genetics services provider. Previously, Andy was Principal for healthcare mergers & acquisitions at Riveron Consulting and held multiple senior positions within Caris Life Sciences and Miraca Life Sciences including VP of sales, business development, and product development. There, Andy built a highly successful de novo business unit for clinical and genomic testing in the hematology and oncology market. Prior to Caris, he was National Marketing Manager for Hematology/Oncology at US Labs/Dianon Systems. Andy was also a Naval Flight Officer and awarded multiple Navy Commendation Medals. Andy received his BS in Physiology from the University of Arizona and an MBA from the University of Florida.
Vice President, Marketing
Yong Yi has over 15 years of experience in the life sciences industry, including key leadership roles in marketing, application support, and R&D. Prior to joining Wafergen in May 2015, Yong was the Marketing Director at Agilent Technologies for next generation sequencing and gene expression microarrays. There, he drove double digit growth of the NGS target enrichment business and led initiatives to bring NGS into the clinic. Yong also spent 10 years at Fluidigm Corporation where he was a key contributor in growing the company from early stage to a successful initial public offering in 2011. At Fluidigm, he launched innovative microfluidic platforms, managed the worldwide applications and support team, and developed new technologies. Yong received his BS and MS in Mechanical Engineering from the University of Illinois at Champaign-Urbana.